On the morning of August 27, 2020, the 13th meeting of the Standing Committee of the 13th National Committee of the CPPCC concluded in Beijing.
, the meeting adopted the decision to add Bi Jingquan as a member of the 13th National Committee of the Chinese People's Political Consultative Conference and deputy director of the Economic Commission.
the news, the pharmaceutical industry was in a state of boiling.
Two years ago, Bi Jingquan, then secretary and deputy director of the Party Group of the State Administration of Market Supervision and Administration and former head of the State Food and Drug Administration, was asked to resign over the vaccine case against Jilin Changchun Changsheng Company, which caused great reaction and regret in the pharmaceutical industry.
time, E drug managers have published an article "people regret Bi Jingquan's stay, is to retain the reform has been launched and it brings excitement and hope."
today, the 65-year-old, who has not returned to the pharmaceutical industry, is in the public eye in a new capacity that still seems to be a source of comfort for the industry, which is still looking forward to drug regulatory reform.
01 Bi Jingquan's new place According to the CPPCC network, the meeting voted to add a total of five members of the 13th CPPCC National Committee, namely Bi Jingquan, Miao Yu, Hu Zejun, Liang Wei, Yu Shugang.
, the addition of Bi Jingquan, Miao Wei as deputy director of the Economic Commission.
The five new CPPCC members have previously held important positions in various ministries and other units, such as Miao Yu, who previously served as party secretary of the Ministry of Industry and Information Technology, Hu Zejun, who served as auditor-general of the Audit Office, Liang Wei, who was the head of the Personnel Bureau of the CPPCC General Office, and Yu Shugang, who was previously the Minister of Culture and Tourism.
And Bi Jingquan worked in the National Development and Reform Commission for many years, after the State Council Deputy Secretary-General, members of the organ party group was raised to the State Food and Drug Administration as director, party secretary, after institutional reform, the State Administration of Market Supervision and Administration party group secretary, deputy director.
is worth noting that, according to the public information available, all four of them were born in 1955 and are now 65 years old.
in accordance with the general implied rules, many provincial and ministerial officials usually go to the National People's Congress or the CPPCC "back to the second line" after leaving office, to continue to carry out their duties.
addition of CPPCC members this time, basically belong to this situation.
And industry sources told E-Drug managers that the 65-year-old Bi Jingquan was added as a member of the National Committee of the Chinese People's Political Consultative Conference and served as deputy director of the Economic Commission, to a large extent, the drug regulatory authority under the administration of the achievements of drug reform has been fully recognized.
Committee of the Chinese People's Political Consultative Conference (CPPCC) is one of the ten special committees under the CPPCC National Committee.
Among them, the responsibilities and objectives of the Economic Commission are to conduct in-depth investigation and research on the general policy of the country and some important issues in economic and social development, and to make suggestions to the CPC Central Committee and the State Council through research reports, CPPCC information and speeches to the General Assembly.
02 Five years before the fifth anniversary of the drug review reform, on August 18, 2015, the State Council officially issued the Opinions on Reforming the Drug Medical Device Review and Approval System.
since then, a vast drug review reform has begun.
and Bi Jingquan are seen as key figures in kicking off the reform.
, the pharmaceutical industry has indeed experienced unprecedented changes and changes.
speed up of drug review and approval, the promotion of consistent evaluation of generic drug quality and efficacy, the pilot and landing of MAH system... A series of reforms are moving forward quickly.
that's why there has been a long-standing industry call for Bi Jingquan to return to the drug regulatory system.
, as E-Drug managers have previously written, people lament Bi Jingquan's stay in order to retain the reforms that have been initiated and the excitement and hope it brings.
now people are pleased that Bi Jingquan is back in his new job, no doubt as a blessing to the changers, but also to the industry he once threw himself into can have a better development expectations.